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Background: The prognostic value of metastasis-associated gene 1 (MTA1) in nasopharyngeal carcinoma (NPC) has
been suggested. However, there is still no direct evidence that MTA1 promotes NPC growth in vivo. In this study,
we aimed to investigate the function of MTA1 in the regulation of NPC cell proliferation and tumorigenesis in vitro
and in vivo.
Methods: Stable MTA1 knockdown or overexpression NPC cell lines were employed. The effects of MTA1 depletion
or overexpression on cell proliferation, colony formation, cell cycle progression were examined by MTT, colony
formation and flow cytometry assay. The effects of MTA1 depletion on tumor growth in vivo were examined in
mouse xenograft model.
Results: MTA1 knockdown or overexpression drastically changed the proliferation, colony formation and cell cycle
of NPC cells in vitro. MTA1 depletion significantly suppressed NPC tumorigenesis in vivo.
Conclusion: MTA1 promotes NPC cell proliferation via enhancing G1 to S phase transition, leading to increased
tumor growth. Targeting MTA1 is a promising approach to reduce tumor burden of NPC.
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Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nant tumor with a high incidence in southern China and
Southeast Asia. Radiotherapy is a dominant treatment
approach for NPC. Primary tumor volume (GTV-P) is
known to be positively correlated with the prognosis of
NPC [1,2]. Despite recently increased use of intensity-
modulated radiation therapy (IMRT), GTV-P is still an
independent prognostic indicator for treatment outcome
of NPC, and has correlations with T classification, cervical
lymph node metastasis as well as post-treatment distant
metastasis [3,4]. Tumor volume is known to be positively
correlated with the proliferation ability of tumor cells.
Thus further understanding of molecular mechanisms
underlying abnormal proliferation of NPC cells will help
develop novel options for the diagnosis, therapy and prog-
nosis of NPC.* Correspondence: zhuxx011@163.com
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reproduction in any medium, provided the orMetastasis-associated gene 1 (MTA1) has been impli-
cated in the carcinogenesis and metastasis of a variety of
human cancers [5-7]. In particular, recent studies suggest
the prognostic value of MTA1 in NPC because MTA1
overexpression was an independent prognostic factor for
poor overall survival of NPC patients [8,9]. Our recent
study provided direct evidence that MTA1 regulated actin
cytoskeleton reorganization to promote NPC metastasis
[7]. However, the role of MTA1 in NPC cell proliferation
is not clear.
In the present study, we employed both gain and loss
of function approaches to investigate the role of MTA1
in NPC growth. We examined the effects of MTA1
overexpression or knockdown on NPC cell proliferation,
cell-cycle distribution, and colony formation in vitro. In
addition, we evaluated the effects of MTA1 knockdown
on NPC xenograft growth in nude mice. Our results
showed that MTA1 promoted NPC growth in vitro and
in vivo.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Cell culture
Stable MTA1 knockdown NPC cell lines (CNE1/MTA1-si
and C666-1/MTA1-si), stable MTA1 overexpression NPC
cell line (NP69/MTA1), and their corresponding control
cells (CNE1 or C666-1/CTL-si, and CNE1, C666-1 or
NP69/NC) were constructed and cultured as described
in previous study [7]. CNE1 were well-differentiated
NPC cells, C666-1 were undifferentiated NPC cells, and
NP-69 were immortalized NPC cells.
Cell proliferation assay
The cells were plated into 96-well plates at the density
of 5,000 cells/well and cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum for 1, 2, 3, 4,Figure 1 MTA1 promotes the growth of NPC cells in vitro. (A) MTT pro
lines and control cells. (B) Representative images of colony formation assay of
cells. (C) Flow cytometry analysis of cell-cycle distribution of MTA1 knockdown
independent experiments. CTL-si versus WT: P > 0.05; **P < 0.01, ***P < 0.001 c5, 6 and 7 days, respectively. Then cells were incubated
with 20 μL MTT [3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide] (5 mg/mL) (Promega,
Shanghai, China) for additional 4 h, and 100 μL DMSO
was added into each well to dissolve the formazan prod-
uct. The absorbance of the enzyme was measured at 490
nm using an Microplate Reader (Bio-Rad, Hercules, CA,
USA). Cell growth rates (average absorbance of each
group) were then calculated. All experiments were
performed in triplicate samples and repeated at least three
times.
Colony formation assay
The cells were grown in 6-well plates and cultured in a
humidified incubator at 37°C and 5% CO2. The cells wereliferation assay of MTA1 knockdown cell lines, MTA1 overexpression cell
MTA1 knockdown cell lines, MTA1 overexpression cell lines and control
C666-1 cells and control cells. All results were reproducible in three
ompared to CTL-si. # P < 0.001 compared to NC. OD, optical density.
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formed (14 days). The colonies were fixed with methanol
for 15 min, stained with hematoxylin for 10–15 min, and
colonies containing >50 cells were counted. The rate of
colony formation was indicated by the ratio of the number
of colonies over the number of seeded cells. The experi-
ment was repeated three times, and a mean value was
presented.
Cell cycle analysis
Cell cycle distribution was detected by using Cycletest
Plus DNA Reagent kit (Becton Dickinson, USA). The
protocol recommended by BD Bioscience was followed.
The samples were run with a FACScan flow cytometer
(Becton Dickinson, USA) and the results obtained were
analyzed using the ModFit software.Figure 2 MTA1 depletion inhibits NPC tumorigenesis in vivo. (A) MTA1
flank of nude mice. Control cells were injected subcutaneously into the left
MTA1 knockdown cells produced smaller tumors than control cells. (B) Gro
of 5 mice. (C) The tumor from each group was weighed immediately after th
**P < 0.01, ***P < 0.001 as compared to CTL-si.Xenograft model
Female athymic BALB/c nu/nu mice (4–6 weeks old)
were purchased from Guangdong Medical Laboratory
Animal Center (Guangzhou, China). All protocols for
animal studies were reviewed and approved by Animal
Care and Use Committee of Southern Medical University.
1 × 107 cells from individual cloned cell lines were
injected subcutaneously into the left flank and right
flank of nude mice (n = 5 per group). After 10 days of
implantation of tumor cells, tumors were measured
with calipers every 3 days. Tumor volume was calcu-
lated according to the following formula: V = (L*W2*π)/
6, V, volume (mm3); L, biggest diameter (mm); W,
smallest diameter (mm) [10]. At the end of experiments,
the mice were euthanized and tumors were excised and
weighed.knockdown NPC cells were injected subcutaneously into the right
flank of the same nude mice (n = 5). At 3 weeks after implantation,
wth curve of tumor volumes. Each data point represented mean ± SD
e dissection. The average tumor weight was indicated as mean ± SD.
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Immunohistochemical staining was performed using
standard protocol. Briefly, cryosections were stained
with primary antibodies for MTA1 (1:200; Abcam,
USA) and Ki67 (1:200; Abcam, USA), followed by incu-
bation with secondary antibodies. A stained cell was
considered as positive cell. All results of immunohis-
tochemical staining were double-blinded judged by
different pathologists.
Statistical analysis
All data were presented as the mean ± standard deviation
of at least three independent experiments. The two-tailed
unpaired Student’s t test was used to assess differences in
cell growth rate, colony formation, cell cycle distribution,
tumor weight, tumor volume and immunohistochemistry
stained cell count between groups. P < 0.05 was considered
statistically significant.
Results
MTA1 regulates NPC cell growth in vitro
First we examined the effect of endogenous MTA1
knockdown on NPC cell growth. MTT assay showed
that MTA1 knockdown reduced the cell growth rate by
44% in C666 cells (P < 0.001) and by 30% in CNE1 cells
(P < 0.001) (Figure 1A). Colony formation assay showedFigure 3 Immunohistochemistry staining of Ki67 in mouse xenograft
tissues derived from MTA1 knockdown NPC cells, compared with those fromthat MTA1 knockdown resulted in dramatic decrease of
colony-formation efficiency in C666-1 and CNE1 cells,
compared to their corresponding controls (P <0.01;
Figure 1B). These data imply that endogenous MTA1 is
essential to the proliferation and colony formation of
NPC cells.
To further investigate the function of MTA1 in NPC
cell growth, we performed gain-of-function experiments
in immortalized nasopharyngeal epithelial cell NP69.
Compared with the cells transfected with empty vector,
enforced MTA1 overexpression significantly promoted
the growth and colony-formation capacity of NP69 cells
(p < 0.001; Figure 1A and B).
To understand how MTA1 promotes NPC cell prolifera-
tion and colony formation, we examined cell cycle pro-
gression of C666-1 cells depleted of MTA1. Compared
with control cells, C666-1/MTA1-si cells displayed an in-
creased percentage of cells in G1 phase and fewer cells in
G2 phase (p < 0.001), but no significant difference in S
phrase distribution (Figure 1C). The results demonstrate
thatMTA1 knockdown induced cell cycle arrest at G1.
MTA1 depletion inhibits the growth of NPC xenografts
in vivo
To assess the effect of MTA1 on NPC growth in vivo, we
injected MTA1 depleted C666-1 or CNE1 cells, or theirmodels. MTA1 and Ki67 staining was less in subcutaneous tumor
control cells (Magnification, ×200).
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monitored tumor growth. Palpable tumors were first
detected in all mice by day 10 after injection. At the end
of experiments, all the mice developed tumors (Figure 2A).
Compared with control, the average tumor volume in
mice injected with MTA1 depleted C666-1 or CNE1
cells was markedly reduced by more than 60% (p < 0.01;
Figure 2B). The average tumor weight was also sig-
nificantly reduced in MTA1 depleted group (p < 0.01;
Figure 2C).
Further immunohistochemical assessment of the nuclear
antigen Ki-67 was used to estimate cell proliferation. The
results demonstrated that the number of Ki-67 positive
cells was significantly decreased in tumor nodules origin-
ating from MTA1 depleted cells, compared to control cells
(Figure 3).
Discussion
MTA1 has been shown to be overexpressed in human
cancers [5]. However, the clinicopathological evidence
to support the correlation of MTA1 overexpression
with tumor growth is limited. Only one report demon-
strated that MTA1 overexpression was associated with
larger tumor size in hepatocellular cancer [11]. Several
studies examined the clinicopathological significance
of MTA1 in NPC, but found no association between
increased MTA1 expression and T-stage [8,9]. This
may be due to the limitations of current T staging
system of NPC for determining tumor burden [3]. The
inclusion of tumor volume into TNM staging system
has been proposed [3,4]. Thus the biological relevance
of MTA1 to NPC growth and tumor volume need to be
further investigated.
In fact, MTA1 is clearly involved in breast cancer
growth. Antisense of MTA1 inhibited the growth of highly
metastatic breast cancer cell lines [12]. Moreover, forced
expression of MTA1 nhanced the ability of breast cancer
cell line MCF-7 to grow in an anchorage-independent
manner [13]. MTA1 controbutes to inappropriate devel-
opment of mammary glands, hyperplastic nodules and
mammary tumors [14,15]. In our study, we transfected
MTA1 cDNA into immortalized nasopharyngeal epithelial
cell and showed that enforced expression of MTA1 con-
tributed to increased cell growth and colony formation,
consistent with the results by Mahoney et al. [16]. We fur-
ther examined the therapeutic value of MTA1 siRNA and
found that downregulation of MTA1 by RNAi successfully
suppressed the growth of C666-1 NPC cells in vitro and
in vivo, suggested that MTA1 is a promising target for
NPC gene therapy.
The abnormal cell cycle is crucial to the proliferation
of cancer cells. Different from our findings in lung can-
cer cells [17], in the present study, we provided evidence
that MTA1 knockdown induced G1 arrest of NPC cells,suggesting that MTA1 promotes aberrant G1 to S phase
transition, leading to increased proliferation and tumori-
genicity of NPC cells. These divergent findings suggest
that the effect of MTA1 on tumor cell growth and cell
cycle progression are cell dependent. Cell cycle is regu-
lated by a variety of signaling pathways, among which
p53 pathway is a crucial regulator of cell cycle and apop-
tosis of cancer cells [18]. Emerging data suggest that
MTA1 had deacetylation activity on p53 and subse-
quently attenuated the transactivation function of p53
[19,20]. MTA1 was also identified as a p53-independent
transcriptional corepressor of p21 (WAF1), which is a
direct target of p53 and mediates p53-dependent G1
growth arrest [21].
Conclusions
In summary, we found that MTA1 knockdown in NPC
cells decreases cell proliferation in vitro via the induc-
tion of G1 phase arrest and drastically suppresses tumor
formation in vivo. These findings suggest that targeting
MTA1 is a promising approach to reduce tumor burden
of NPC.
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